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Background
Anti-tumor necrosis factor (TNF) – infliximab is known
to decrease disease activity of juvenile idiopathic arthri-
tis (JIA) but its effect on longitudinal growth in relation
to puberty is not clear.
Aim
To assess the dynamics of longitudinal growth in prepu-
bertal and pubertal patient’s with JIA in response to
infliximab, to evaluate effectiveness of the therapy.
Materials and methods
Study included 13 children, 8 of the prepubertal and 5 -
the puberty. The study was subjected to information
about sex, age, children’s growth, diagnosis, therapy.
Growth was estimated by measuring and comparing
patient’s height standard deviation score(SDS) in rela-
tion to the midparental height, the change of this value
(ΔhSDS) from -1 to 0 and 0 to 1 year of treatment and
the change between the ΔhSDS values to assess growth
improvement. Treatment efficacy was assessed according
to criteria ACR pedi. Infliximab was administered in
connection with ineffectiveness of standard antirheu-
matic therapy (methotrexate, leflunamide, cyclosporine
A, methotrexate + cyclosporine A combination).
Results
9 of all 13 children (69,2%) were with systemic JIA, 2 of all
13 children (15,4%) – poliarticular JIA, other 2 of 13 chil-
dren (15,4%) – juvenile spondyloarthritis. Before inflixi-
mab theatment all children were with 3-2 degrees of
disease activity. After a year of infliximab 53.8% of patients
demonstrated response ACR pedi70, 30,8% of patients -
ACR pedi 50, 15,4% - ACR pedi 30. In the prepubertal
group the relation height SDS (mean ± standart error of
the mean) was -1.53 ± 1,-2.07 ± 1 and 1.45 ±1.61 at -1, 0
and 1 year of infliximab treatment respectively. The
ΔhSDS before infliximab was -0.54 ± 0.27, over the first
year with infliximab ΔhSDS was 0.62 ± 0.9(p>0,05). In the
pubertal group the SDS was-1, 39 ± 2.36, -3.12 ± 2.6, and
-3.12 ± 2.61 at -1, 0 and 1 year of treatment respectively.
The ΔhSDS before infliximab was -0.73 ± 0.43, over the
first year with infliximab ΔhSDS was -0.004 ± 0.47
(p>0,05). Individual analysis of each patient revealed that
most children of the pubertal group (3 / 5) and the prepu-
bertal group (6 / 8) showed improvement in longitudinal
growth during treatment with infliximab. Out of the 13
children included in the study prior to the infliximab, 8
received steroids per os. After a year of the treatment in
therapy of 6 children doses of steroids were decreased and
one child no longer needed steroids. The dose of steroids
mg / kg / day to 0 and 1 year of the therapy respectively
was 0.22 -0.1, 0.12 -0.1, 0.1 -0.076 Δdozy.
Conclusions
Infliximab treatment in addition to a significant therapeu-
tic effect also showed an increase of longitudinal growth
in children suffering from idiopathic rheumatoid arthritis.
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